This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, A. R.
Right arrow Articles by Armstrong, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, A. R.
Right arrow Articles by Armstrong, R. W.
Related Collections
Right arrow Health services research
Right arrow Drugs: psychiatry
Right arrow Other drug use
Right arrow Child and adolescent psychiatry
CMAJ • November 27, 2001; 165 (11)
© 2001 Canadian Medical Association or its licensors

Research
Recherche

Prescription of methylphenidate to children and youth, 1990–1996

Anton R. Miller*{dagger}, Christopher E. Lalonde{ddagger}, Kimberlyn M. McGrail and Robert W. Armstrong*{dagger}

From *the Department of Pediatrics, University of British Columbia, and the Children's and Women's Health Centre of British Columbia, Vancouver, BC; {dagger}the Centre for Community Health and Health Evaluation Research, BC Research Institute for Children's and Women's Health, Vancouver, BC; {ddagger}the Department of Psychology, University of Victoria, Victoria, BC; and §the Centre for Health Services and Policy Research and the Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC

Correspondence to: Dr. Anton R. Miller, Centre for Community Health and Health Evaluation Research, BC Research Institute for Children's and Women's Health, Room L408, 4480 Oak St., Vancouver BC V6H 3V4; fax 604875-3569; amiller{at}cw.bc.ca

Background: There are concerns about the frequency and appropriateness of psychostimulant drug prescription to children. In order to identify unusual or unexpected patterns of use or prescribing, we reviewed prescription of methylphenidate (Ritalin) to children and adolescents aged 19 years or less in British Columbia between 1990 and 1996.

Methods: We obtained information about patients, physicians and prescriptions from British Columbia's Triplicate Prescription Program database for controlled drugs. Prescription data were available for the period Jan. 1, 1990, to Dec. 31, 1996. Linkage with the BC Linked Health Dataset provided additional demographic and health information.

Results: In 1990, 1715 children received at least 1 prescription for methylphenidate (1.9 per 1000 children). By 1996, the number had increased to 10 881 children (11.0 per 1000). Because some children were prescribed methylphenidate in more than 1 year, we also calculated the frequency with which the drug was prescribed to children who had never received it before. This rate increased from 1.0 per 1000 children in 1990 to 4.7 per 1000 in 1995; the rate fell in 1996 to 3.5 per 1000. The number of children receiving methylphenidate varied across health regions of the province, from 12.0 to 35.4 per 1000. Use also varied by socioeconomic status quintile: in the 2 lowest (least privileged) quintiles, 21.6 per 1000 children received methylphenidate, compared with 18.4 per 1000 in the 3 highest quintiles (relative risk 1.2, 95% confidence interval 1.1–1.2). Pediatricians and psychiatrists wrote 23% and 21% of all prescriptions respectively. General practitioners accounted for 56% of all prescriptions and 41% of initial methylphenidate prescriptions. A claim for prior specialist consultation was found in 30% of such cases. Many of the children who received more than 10 prescriptions had seen 4 or more physicians. The average daily dosage prescribed differed little among general practitioners, pediatricians and psychiatrists, unlike the mean interval between successive prescriptions: 89.9 (standard deviation [SD] 68.2), 99.8 (SD 64.1) and 75.9 (SD 70.2) days respectively. Persistence with therapy was more likely when a psychiatrist provided the initial prescription, or with involvement of more than one specialty.

Interpretation: Many trends and practices in the prescription of methylphenidate to children in British Columbia are consistent with other settings and accepted standards. Some aspects warrant closer investigation, including regional and socio-economic discrepancies in the distribution of patients, the relative involvement of primary and specialist care providers, continuity of care issues and time intervals between prescriptions.




This article has been cited by other articles:


Home page
 CMAJHome page
L. A. Strohschein
Prevalence of methylphenidate use among Canadian children following parental divorce
Can. Med. Assoc. J., June 5, 2007; 176(12): 1711 - 1714.
[Abstract] [Full Text] [PDF]

Home page
 Qual Health ResHome page
D. L. Hansen and E. H. Hansen
Caught in a Balancing Act: Parents' Dilemmas Regarding Their ADHD Child's Treatment With Stimulant Medication
Qual Health Res, November 1, 2006; 16(9): 1267 - 1285.
[Abstract] [PDF]

Home page
 Am J Health Syst PharmHome page
F. D. C. Goodman and P. Glassman
Evaluating potentially aberrant outpatient prescriptions for extended-release oxycodone
Am. J. Health Syst. Pharm., December 15, 2005; 62(24): 2604 - 2608.
[Full Text] [PDF]

Home page
 PediatricsHome page
J. C. Brehaut, A. Miller, P. Raina, and K. M. McGrail
Childhood Behavior Disorders and Injuries Among Children and Youth: A Population-Based Study
Pediatrics, February 1, 2003; 111(2): 262 - 269.
[Abstract] [Full Text] [PDF]